A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
There is an urgent need to understand the clinical and economic consequences associated with AKI in hospitalized patients with COVID-19 to better inform treatment decisions...
The SARS-Cov-2 delta variant has filled U.S. hospitals to capacity reinforcing the need for data to better understand disease severity and support evidence-based treatment decisions...
Premier Applied Sciences and Meitheal Pharmaceuticals collaborate to study anticoagulant use in COVID-19 patients.
Forbes | A new study conducted via the U.S. Premier Healthcare Database revealed nearly one in every four Covid-19 deaths may be attributed to hospital strain.
See how we're leveraging our rich data sets to uncover new oncology insights.
Financial Times | Premier's Roni Christopher weighs in on the FDA's approval of a Biogen treatment for patients with Alzheimer's disease.
Premier Applied Sciences to analyze study results and evaluation of the product aimed at improving outcomes and lowering costs for male urinary disorders.
JAMA Network | This paper examines the uptake and accuracy of diagnosis for COVID-19 in U.S. hospitals.
TCTMD | Premier's Ning Rosenthal discusses findings from a recent study that looked at patients with COVID-19 in US acute care hospitals.
GE Healthcare | GE Healthcare and Premier Applied Sciences® selected St. Luke’s as an ideal pilot site for the One-Stop Clinic breast care model.
JAMA Network | Using the Premier Healthcare Database, this study looked at patients with COVID-19 in US acute care hospitals and high ICU admission and in-hospital mortality rates.
The Journal of Population Health Management | This study used a performance platform to enhance clinicians' management of patients with diabetes and osteoporosis.